Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Evan A Stein, MD
LIB Therapeutics LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Midwest Institute for Clinical Research
Indianapolis, Indiana, United States
- Louisville Metabolic and Atherosclerosis Research Center
Louisville, Kentucky, United States
- Metabolic & Atherosclerosis Research Center (marc)
Cincinnati, Ohio, United States
- Sterling Research Group
Cincinnati, Ohio, United States
- the Lindner Research Center
Cincinnati, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 May 2018
- Primary completion
- 9 Nov 2018
- Completion
- 30 Nov 2018
- Last update posted
- 18 Feb 2019
- Registered enrollment
- 81
- Registry id
- NCT03549260
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.